Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • 2020 Oncology Reimbursement Meeting

    Contains 6 Component(s) Includes Multiple Live Events. The next is on 07/17/2020 at 2:45 PM (EDT)

    A series of sessions designed to strengthen your program’s operations, accelerate your knowledge in oncology business, and take on this rapidly changing healthcare landscape.

    imageAt the ACCC Oncology Reimbursement Meeting, we can equip you and your colleagues with the tools needed to strengthen your program’s operations, accelerate your knowledge in oncology business, and take on this rapidly changing healthcare landscape.
    In this series of sessions, you'll have the opportunity to:
            • Review the latest trends in oncology coding and billing based on the 2020 Medicare Final Rules
            • Assess financial strategies to track and improve the financial health of your cancer program
            • Gain insight to upcoming coding and reimbursement challenges related to financial counseling, compliance, and authorizations in medical and radiation oncology
            • Identify opportunities to improve the financial navigation services at your practice or program

    Ricky Newton, CPA

    Chief Financial and Operating Officer, Cancer Specialists of Tidewater, Ltd.

    Ricky Newton has over 28 years of experience in the healthcare industry. He currently serves as Director of Financial Services and Operations for the Community Oncology Alliance. Since 1997 he has been the administrator for Cancer Specialists of Tidewater, Ltd. He worked for Riverside Health Systems from July 2007 to July 2014 serving as their director for oncology operations. Prior to joining the practice he was a CPA with the public accounting firm of Failes & Associates. 

    Ricky has presented and consulted at over 350 conferences and practices in 46 states on topics such as financial and practice management issues in medical practices, health care law, relationships between oncologists and hospitals, managing employees, contracting with insurers, pharmacy management including managing pharmaceutical contracts, compensation models as well as other topics in the operating an oncology practice. 

    Currently, Ricky serves as treasurer of the Virginia Association of Hematology and Oncology Managers (VAHOM), Virginia Association of Hematologists and Oncologist (VAHO), Southeastern Coalition of Oncology Practitioner (SCOOP), National Oncology Society Network (NOSN) and Community Oncology Alliance (COA). 

    Ricky graduated with honors in 1990 from Old Dominion University with majors in Accounting and Finance.

    Teri Bedard, BA, RT(R)(T), CPC

    Director, Client Services, Revenue Cycle Coding Strategies

    Teri Bedard is the Executive Director, Client & Corporate Resources with Revenue Cycle Coding Strategies, LLC.  Her expertise includes over 20 years of medical experience.  Teri has served as a senior and Staff Radiation Therapist at renowned oncology practices across the Midwest and during her tenure with RCCS, has served as a Senior Consultant, Remote Solutions Manager, and Director, Client Services.   As a member of the RCCS team Teri advises and leads clients in the areas of billing and reimbursement for technology, monitoring government regulatory information and seeking new business opportunities.    

    Teri completed her Bachelors of Arts degree at the University of Northern Iowa.  She completed her Radiologic Technology certificate at Mayo School for Health Related Sciences in Rochester, MN and her certificate for Radiation Therapy at Fairview University Medical Center in Minneapolis, MN.  She also earned her certification as a Certified Professional Coder (CPC) through the American Academy of Professional Coders (AAPC). 

    Teri is active in the ARRT, ASRT, and AAPC.  She lectures and participates at national seminars in conjunction with the AAPC, ACCC, ACRO, and ASRT.  

    Ron DiGiaimo, MBA, FACHE

    CEO, Revenue Cycle Coding Strategies

    As CEO, Ron leads Revenue Cycle Inc. with more than 27 years in clinical, mid-level and executive level management, clinical experience and financial management. He is also a proven strategist in practice building, coding and documentation for both Part A and Part B reimbursement and has broad experience with marketing, operations, development and public relations.

    Ron is active with ACRO, ASTRO, SROA, ACCC, ACE, AAMD, ASCO, ACHE and several other groups whose missions forward the cause of oncology. He currently assists with the publication of the American College of Radiation Oncology Practice Management Guide, which serves to educate the oncology community as a whole.

    Ron earned an MBA from Oklahoma Christian University a bachelor of science in health services administration from Weber State University, Utah and an associate's degree in radiography from MCC in Waco, Texas. His clinical and strong operational management experience assist in both short and long term goal achievement for hospitals and providers alike.

    Dan Sherman, MA, LPC

    Financial Navigator/Consultant, The NaVectis Group

    Dan E. Sherman, MA, LPC, has been in the field of financial navigation services for oncology patients since 2008, and is the founder and president of the NaVectis Group, a consulting company that assists oncology providers in the implementation of financial navigation programs. In 2009, he created and implemented the Financial Navigation Program at the Lacks Cancer Center, and has since been recognized by the Oncology Roundtable, Access Management, and the Association of Community Cancer Centers’ Oncology Issues for his expertise in clinical financial navigation. He has also been published in the Journal of Access Management, ACCC’s Oncology Issues journal, the American Journal of Managed Care, and ASCO’s Journal of Oncology Practice. 
    Dan has a degree in accounting, psychology, and a master’s in counseling.

    I can't login or view sessions. What do I do? 

    First, make sure you are using Chrome, Firefox, or Microsoft Edge. The system does not work with Internet Explorer. Then, check to verify that you are logged in.

    How do I access the sessions?

    You can access any of the sessions by clicking on the “Sessions” tab.

    From there, select the session you would like to view. Click on the title and you will see a button to the right of the session title. If the session will begin in the next 15 minutes, the button will say "Early Event Login is Open". If the session has started, it will say "Live Event in Progress". If you do not see one of those buttons, you may need to refresh your screen, especially if you log in more than 15 minutes before the session starts. 

    I am having audio trouble. How can I fix that?

    If you are not able to hear any audio through your computer speakers first check to make sure your speakers are not muted or turned off.  

    The next step is to refresh your screen by pressing the F5 key on your keyboard or clicking the “refresh” button in your web browser. 

    For technical issues, including slides that are not loading, please read the following.

    Please ensure your organization meets hardware, software and bandwidth requirements well in advance 

    Step 1: Browser Tests

    Please take the following browser test: https://zoom.us/test

    Step 2: Please review the following Technical Requirements and be sure your system and networks are up to date.

    Minimum System Requirements:

    2.0Ghz Processor or faster 2 GB RAM (Greater than 2 GB recommended) Minimum Browser Requirements:  

    Browser must support HTML-5. To detect your browser version, run https://whichbrowser.net/  

    Windows 7 or later Mac OS X 10.9 or later Chrome 60 or greater Firefox 52 or greater Edge 14  or greater Safari 10 or greater iOS 10 or greater Internet Explorer 11 IP Addresses and Ports to Allow for HTML5:   72.32.161.112 port 80, 443 (web and audio) 72.32.200.104 port 80, 443 (web and audio) 72.32.221.65 ports 80, 443 (web and audio) 72.32.221.66 ports 80, 443 (web and audio) 67.203.7.114 ports 80, 443 (web and audio)

    Other Recommendations: It is recommended that you use a PC or MAC with an updated Internet Browser. Make sure you have pop-ups blockers disabled in your Internet browser settings. Make sure that your internet browser is Active X enabled. Wifi is not recommended. The problem with WiFi is signal strength can vary causing bandwidth to increase or decrease. We recommend a wired connection. A wired connection gives a consistent signal and consistent bandwidth. A wired connection provides a better experience. Audio (sound) is projected through your computer speakers. Be sure your computer is equipped with speakers or the room where the conference is being broadcast is equipped with speakers  so you can hear the presenters.

    Still having issues? Please email registration@accc-cancer.org

  • Acute Lymphocytic Leukemia: Critical Insights

    Contains 4 Component(s)

    Using a case-based approach, experts discuss current treatment strategies for Ph(+) and Ph(-) patients, and take a closer look at the role of minimal residual disease (MRD) for prognosis and treatment selection.

    Hear critical insights from multidisciplinary cancer team members with expertise in treating older adolescents and adults with acute lymphocytic leukemia (ALL). Using a case-based approach, these experts discuss current treatment strategies for Ph(+) and Ph(-) patients, and take a closer look at the role of minimal residual disease (MRD) for prognosis and treatment selection. Special attention is paid to identification and management of cytokine release syndrome (CRS), along with pertinent drug-drug interactions when using Bcr-Abl tyrosine kinase inhibitors (TKIs) as part of combination treatment. If you have any questions along the way please contact  Monique Dawkins, Assistant Director, Provider Education for ACCC.

  • Acute Lymphocytic Leukemia: Supporting the Patient Journey

    Contains 4 Component(s)

    Listen to perspectives on how to effectively support patients diagnosed with acute lymphocytic leukemia (ALL) throughout the care journey from multidisciplinary cancer team members and a patient representative.

    Listen to perspectives on how to effectively support patients diagnosed with acute lymphocytic leukemia (ALL) throughout the care journey from multidisciplinary cancer team members and a patient representative. Panelists define cohesive communication between the care team and the patient, describe elements required to deliver compassionate care and introduce cost awareness, and discuss how to present treatment risk-benefit analysis. If you have any questions along the way please contact Monique Dawkins, Assistant Director, Provider Education for ACCC.

  • ASCO Direct™ Highlights - Breast Cancer

    Contains 5 Component(s), Includes Credits

    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Release Date:  August 30, 2019
    Expire Date:  August 30, 2020
    Estimated time to complete:  30 minutes

    This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC). 

    This activity is supported in part by educational grants from Astellas and Seattle Genetics, Amgen, Celgene Corporation, Daiichi Sankyo, Inc., Lilly, Merck & Co. Inc., and TESARO, Inc. 

    Target Audience
    The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

    Overview
    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

     Objectives:

    • Review highlights of the advances in clinical and translational research in breast cancer presented at the 2019 ASCO® Annual Meeting.
    • Identify emerging trends and strategies designed to improve the quality of care in breast cancer.
    • Evaluate tools and resources for the management of breast cancer that can be used to achieve effective cancer care delivery and improve the patient experience.

    Your Faculty
    VK Gadi, MD, PhD, University of Washington; Fred Hutchinson Cancer Research Center; Seattle Cancer Care Alliance 

    CONTINUING EDUCATION
    Accreditation Statement

    Jointly Accredited Provider LogoIn support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    IPCE Logo

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.



    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education credit. JA4008106-9999-19-037-H01-P

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information
    For information about the accreditation of this program please contact AXIS at info@axismeded.org. 

    Disclosure of Conflicts of Interest
    AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    VK Gadi, MD, PhD reported a financial interest/relationship or affiliation in the form of Consultant: Seattle Genetics; Novartis Pharmaceuticals Corp; Puma Biotechnology; Biotheranostics. Research grant: Roche; Signal-One Bio; Agendia. Ownership interest: SEngine Precision Medicine. Intellectual property, royalty: SEngine Precision Medicine; PNP Therapeutics; Chimerocyte, Inc.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: 

    Name of Planner/Manager/Reviewer

    Reported Financial Relationship

    John Allan, MD

    Advisor/Consultant: Abbvie, Genentech, Pharmacyclics, Sunesis, Verastem, Bayer, Janssen, AstraZeneca

    Keola Beale, MD

    Nothing to disclose

    Leigh Boehmer, PharmD, BCOP

    Nothing to disclose

    Jennie Crews, MD, MMM, FACP 

    Nothing to disclose

    Stuart P. Feldman, MD

    Nothing to disclose

    Asutosh “Bobby” Gor, MD           

    Nothing to disclose

    Marilyn Haas, PhD, RN, CNS, ANP-BC

    Nothing to disclose

    Ali McBride, PharmD, MS, BCOP

    Advisor: Bristol Myers Squibb

    Chuck Miller, MD              

    Nothing to disclose

    Robert Mocharnuk, MD     

    Common Stock: Merck

    Dee Morgillo, MEd.,CHCP

    Nothing to disclose

    Gene Saylors, MD

    Nothing to disclose

    Mary Stanley

    Nothing to disclose

    Emily Touloukian, DO       

    Nothing to disclose

    Disclaimer  
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Method of Participation and Request for Credit     
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • ASCO Direct™ Highlights - CAR T-Cell Therapy

    Contains 5 Component(s), Includes Credits

    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Release Date:  August 30, 2019
    Expire Date:  August 30, 2020
    Estimated time to complete:  30 minutes

    This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

    This activity is supported in part by educational grants from Astellas and Seattle Genetics, Amgen, Celgene Corporation, Daiichi Sankyo, Inc., Lilly, Merck & Co. Inc., and TESARO, Inc.

    Target Audience
    The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

    Overview
    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Objectives
    At the end of this educational activity, participants should be able to:

    • Review highlights of the advances in clinical and translational research in CAR T-cell therapeutics presented at the 2019 ASCO® Annual Meeting
    • Identify emerging trends and strategies designed to improve the quality of care for patients receiving CAR T-cell therapies 

    Your Faculty
    Keri Maher, DO, MS
    Assistant Professor of Medicine
    Hematopoietic Cellular Therapy and Transplant
    University of Arizona Cancer Center
    University of Arizona, Tucson

    CONTINUING EDUCATION
    Accreditation Statement

    image

    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    image

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.



    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education credit. JA4008106-9999-19-045-H01-P

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information
    For information about the accreditation of this program please contact AXIS at info@axismeded.org.

    Disclosure of Conflicts of Interest
    AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty, Keri Maher, DO, MS, reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: Advisor: Agios Pharmaceuticals.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Name of Planner/Manager/Reviewer

    Reported Financial Relationship

    John Allan, MD

    Advisor/Consultant: Abbvie, Genentech, Pharmacyclics, Sunesis, Verastem, Bayer, Janssen, AstraZeneca

    Keola Beale, MD

    Nothing to disclose

    Leigh Boehmer, PharmD, BCOP

    Nothing to disclose

    Jennie Crews, MD, MMM, FACP 

    Nothing to disclose

    Stuart P. Feldman, MD

    Nothing to disclose

    Asutosh “Bobby” Gor, MD           

    Nothing to disclose

    Marilyn Haas, PhD, RN, CNS, ANP-BC

    Nothing to disclose

    Ali McBride, PharmD, MS, BCOP

    Advisor: Bristol Myers Squibb

    Chuck Miller, MD              

    Nothing to disclose

    Robert Mocharnuk, MD     

    Common Stock: Merck

    Dee Morgillo, MEd.,CHCP

    Nothing to disclose

    Gene Saylors, MD

    Nothing to disclose

    Mary Stanley

    Nothing to disclose

    Emily Touloukian, DO       

    Nothing to disclose

    Disclaimer  
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Method of Participation and Request for Credit     
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • ASCO Direct™ Highlights - Gastrointestinal Cancers

    Contains 5 Component(s), Includes Credits

    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Release Date:  August 30, 2019
    Expire Date:  August 30, 2020
    Estimated time to complete: 45 minutes
    This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

    This activity is supported in part by educational grants from Astellas and Seattle Genetics, Amgen, Celgene Corporation, Daiichi Sankyo, Inc., Lilly, Merck & Co. Inc., and TESARO, Inc.

    Target Audience

    The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

    Overview
    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Objectives
    At the end of this educational activity, participants should be able to:

    • Review highlights of the advances in clinical and translational research in gastrointestinal cancers presented at the 2019 ASCO® Annual Meeting
    • Identify emerging trends and strategies designed to improve the quality of care in gastrointestinal cancers
    • Evaluate tools and resources for the management of gastrointestinal cancers that can be used to achieve effective cancer care delivery and improve the patient experience

    Your Faculty
    Philip Agop Philip, MD, PhD, FRCP
    Kathryn Cramer Endowed Chair in Cancer Research
    Professor of Oncology and Pharmacology
    Leader, GI and Neuroendocrine Oncology
    Vice President of Medical Affairs
    Karmanos Cancer Institute
    Wayne State University
    Detroit, MI 

    CONTINUING EDUCATION
    Accreditation Statement

    image

    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    image

    This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.



    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.75 contact hours of continuing pharmacy education credit. JA4008106-9999-19-039-H01-P

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.75 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information
    For information about the accreditation of this program please contact AXIS at info@axismeded.org.

    Disclosure of Conflicts of Interest
    AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

    The faculty, Philip Agop Philip, MD, PhD, FRCP, reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: Advisor: AbbVie Inc.; Caris Diagnostics Inc.; Celgene Corporation; Eisai Inc.; Halozyme Inc.; Ipsen Biopharmaceutical Inc.; Lexicon Pharmaceuticals Inc.; Lilly USA; Merck & Co, Inc.;  Novartis Pharmaceuticals Corp; Rafael Pharmaceuticals Inc.; Taiho Oncology Inc; Biolinx; Forty Seven Inc. Consultant: AbbVie Inc.; Celgene Corporation; Lilly USA; Merck & Co, Inc.;  Rafael Pharmaceuticals Inc Contracted Research: AAA Pharmaceutical Inc.;  Astellas Pharma Global Development Inc.; Boston Biomedical Pharma Inc.; Bristol-Myers Squibb Co.; Celgene Corporation; Daiichi Sankyo Inc.; Eisai Inc.; Gilead Sciences Inc.; Halozyme Inc.; Incyte Corporation; Lilly USA; Merck & Co, Inc.; Novocure; QED Therapeutics; Taiho Oncology Inc.; Biolinx; Thyme; Bayer Pharmaceuticals Corp; Forty Seven Inc. Data and Safety Monitoring Board: ASLAN Pharmaceuticals; Blueprint Medicines; Erytech Pharma SA; Lexicon Pharmaceuticals Inc. Serve(d) as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Co.; Celgene Corporation;  Ipsen Biopharmaceutical Inc.; Merck & Co, Inc.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Name of Planner/Manager/Reviewer

    Reported Financial Relationship

    John Allan, MD

    Advisor/Consultant: Abbvie, Genentech, Pharmacyclics, Sunesis, Verastem, Bayer, Janssen, AstraZeneca

    Keola Beale, MD

    Nothing to disclose

    Leigh Boehmer, PharmD, BCOP

    Nothing to disclose

    Jennie Crews, MD, MMM, FACP 

    Nothing to disclose

    Stuart P. Feldman, MD

    Nothing to disclose

    Asutosh “Bobby” Gor, MD           

    Nothing to disclose

    Marilyn Haas, PhD, RN, CNS, ANP-BC

    Nothing to disclose

    Ali McBride, PharmD, MS, BCOP

    Advisor: Bristol Myers Squibb

    Chuck Miller, MD              

    Nothing to disclose

    Robert Mocharnuk, MD     

    Common Stock: Merck

    Dee Morgillo, MEd.,CHCP

    Nothing to disclose

    Gene Saylors, MD

    Nothing to disclose

    Mary Stanley

    Nothing to disclose

    Emily Touloukian, DO       

    Nothing to disclose

    Disclaimer  
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Method of Participation and Request for Credit     
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • ASCO Direct™ Highlights - Genitourinary Cancers

    Contains 5 Component(s), Includes Credits

    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Release Date:  August 30, 2019
    Expire Date:  August 30, 2020
    Estimated time to complete:  30 minutes

    This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

    This activity is supported in part by educational grants from Astellas and Seattle Genetics, Amgen, Celgene Corporation, Daiichi Sankyo, Inc., Lilly, Merck & Co. Inc., and TESARO, Inc.

    Target Audience

    The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

    Overview
    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Objectives
    At the end of this educational activity, participants should be able to:

    • Review highlights of the advances in clinical and translational research in genitourinary cancers presented at the 2019 ASCO® Annual Meeting
    • Identify emerging trends and strategies designed to improve the quality of care in genitourinary cancers
    • Evaluate tools and resources for the management of genitourinary cancers that can be used to achieve effective cancer care delivery and improve the patient experience

    Your Faculty
    Sumanta Kumar Pal, MD
    Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research
    Co-Director, Kidney Cancer Program
    City of Hope 

    CONTINUING EDUCATION
    Accreditation Statement

    image

    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    image

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.



    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education credit. JA4008106-9999-19-042-H01-P

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours. 

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information
    For information about the accreditation of this program please contact AXIS at info@axismeded.org.

    Disclosure of Conflicts of Interest
    AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty, Sumanta Kumar Pal, MD, reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:  Consultant: GlaxoSmithKline; Bristol Myers Squibb Company, Inc.; Pfizer, Inc.; Exelixis, Inc.; Astellas Pharma US

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Name of Planner/Manager/Reviewer

    Reported Financial Relationship

    John Allan, MD

    Advisor/Consultant: Abbvie, Genentech, Pharmacyclics, Sunesis, Verastem, Bayer, Janssen, AstraZeneca

    Keola Beale, MD

    Nothing to disclose

    Leigh Boehmer, PharmD, BCOP

    Nothing to disclose

    Jennie Crews, MD, MMM, FACP 

    Nothing to disclose

    Stuart P. Feldman, MD

    Nothing to disclose

    Asutosh “Bobby” Gor, MD           

    Nothing to disclose

    Marilyn Haas, PhD, RN, CNS, ANP-BC

    Nothing to disclose

    Ali McBride, PharmD, MS, BCOP

    Advisor: Bristol Myers Squibb

    Chuck Miller, MD              

    Nothing to disclose

    Robert Mocharnuk, MD     

    Common Stock: Merck

    Dee Morgillo, MEd.,CHCP

    Nothing to disclose

    Gene Saylors, MD

    Nothing to disclose

    Mary Stanley

    Nothing to disclose

    Emily Touloukian, DO       

    Nothing to disclose

    Disclaimer  
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Method of Participation and Request for Credit     
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • ASCO Direct™ Highlights - Genomics

    Contains 5 Component(s), Includes Credits

    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Release Date:  August 30, 2019
    Expire Date:  August 30, 2020
    Estimated time to complete:  45 minutes

    This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

    This activity is supported in part by educational grants from Astellas and Seattle Genetics, Amgen, Celgene Corporation, Daiichi Sankyo, Inc., Lilly, Merck & Co. Inc., and TESARO, Inc.

    Target Audience
    The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

    Overview
    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Objectives
    At the end of this educational activity, participants should be able to:

    • Review highlights from studies focused on cancer genomics presented at the 2019 ASCO® Annual Meeting
    • Identify emerging trends and strategies in cancer genomics and molecular diagnostics that can be used to monitor clinical efficacy of treatment and improve patient outcomes

    Your Faculty
    Jeffrey Gregg, MD
    Senior Director, Clinical Pathology
    Director, Molecular Diagnostics
    Professor of Pathology
    Department of Pathology and Laboratory Medicine
    University of California, Davis Medical Center
    Scientific Advisor, Liquid Biopsy, Foundation Medicine, Inc.

    CONTINUING EDUCATION
    Accreditation Statement

    image

    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    image

    This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.



    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.75 contact hours of continuing pharmacy education credit. JA4008106-9999-19-047-H01-P

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.75 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information
    For information about the accreditation of this program please contact AXIS at info@axismeded.org.

    Disclosure of Conflicts of Interest
    AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty, Jeffrey Gregg, MD, reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: Consultant: Foundation Medicine, Inc. Serve(d) as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Co; AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corp. Research grant: AstraZeneca Pharmaceuticals LP.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Name of Planner/Manager/Reviewer

    Reported Financial Relationship

    John Allan, MD

    Advisor/Consultant: Abbvie, Genentech, Pharmacyclics, Sunesis, Verastem, Bayer, Janssen, AstraZeneca

    Keola Beale, MD

    Nothing to disclose

    Leigh Boehmer, PharmD, BCOP

    Nothing to disclose

    Jennie Crews, MD, MMM, FACP 

    Nothing to disclose

    Stuart P. Feldman, MD

    Nothing to disclose

    Asutosh “Bobby” Gor, MD             

    Nothing to disclose

    Marilyn Haas, PhD, RN, CNS, ANP-BC

    Nothing to disclose

    Ali McBride, PharmD, MS, BCOP

    Advisor: Bristol Myers Squibb

    Chuck Miller, MD                 

    Nothing to disclose

    Robert Mocharnuk, MD     

    Common Stock: Merck

    Dee Morgillo, MEd.,CHCP

    Nothing to disclose

    Gene Saylors, MD

    Nothing to disclose

    Mary Stanley

    Nothing to disclose

    Emily Touloukian, DO        

    Nothing to disclose

     

    Disclaimer  
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Method of Participation and Request for Credit
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • ASCO Direct™ Highlights - Gynecologic Cancers

    Contains 5 Component(s), Includes Credits

    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Release Date:  August 30, 2019
    Expire Date:  August 30, 2020
    Estimated time to complete:  30 minutes

    This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).
    This activity is supported in part by educational grants from Astellas and Seattle Genetics, Amgen, Celgene Corporation, Daiichi Sankyo, Inc., Lilly, Merck & Co. Inc., and TESARO, Inc.

    Target Audience
    The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

    Overview
    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Objectives
    At the end of this educational activity, participants should be able to:

    • Review highlights of the advances in clinical and translational research in gynecologic cancers presented at the 2019 ASCO® Annual Meeting
    • Identify emerging trends and strategies designed to improve the quality of care in gynecologic cancers
    • Evaluate tools and resources for the management of gynecologic cancers that can be used to achieve effective cancer care delivery and improve the patient experience

    Your Faculty
    Bradley J. Monk, MD, FACS, FACOG
    Professor
    Division of Gynecologic Oncology
    Arizona Oncology (US Oncology Network)
    University of Arizona College of Medicine
    Creighton University School of Medicine at St. Joseph's Hospital Phoenix, USA
    Medical Director
    US Oncology Research Network - Gynecologic Program 

    CONTINUING EDUCATION
    Accreditation Statement

    image

    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    image

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.



    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education credit. JA4008106-9999-19-041-H01-P 

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours. 

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information
    For information about the accreditation of this program please contact AXIS at info@axismeded.org.

    Disclosure of Conflicts of Interest
    AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty, Bradley J. Monk, MD, FACS, FACOG, reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: Consultant: AbbVie, Inc.; Advaxis, Inc., Agenus; Amgen;  AstraZeneca Pharmaceuticals LP; ChemoCare; ChemoID; Clovis Oncology; Conjupro Bio-Pharmaceuticals; Easai, Inc.; Geistlich Pharma; Genmab; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte Corporation; Janssen Pharmaceuticals, Inc. - a pharmaceutical company of Johnson & Johnson; Mateon (Oxigene, Inc.); Merck & Co., Inc., Myriad Genetics, Inc.; NuCana; OncoMed Pharmaceuticals; OncoQuest, Inc.; OncoSec Medical Incorporated; Perthera, Inc.; Pfizer, Inc.; Precision Oncology; Puma Biotechnology; Genentech/Roche; Samumed; Takeda Oncology; Tesaro; VBL Therapeutics.  Serve(d) as a speaker or a member of a speakers bureau for:  AstraZeneca Pharmaceuticals LP; Clovis Oncology; Janssen Pharmaceuticals, Inc. - a pharmaceutical company of Johnson & Johnson; Genentech/Roche; Tesaro.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Name of Planner/Manager/Reviewer

    Reported Financial Relationship

    John Allan, MD

    Advisor/Consultant: Abbvie, Genentech, Pharmacyclics, Sunesis, Verastem, Bayer, Janssen, AstraZeneca

    Keola Beale, MD

    Nothing to disclose

    Leigh Boehmer, PharmD, BCOP

    Nothing to disclose

    Jennie Crews, MD, MMM, FACP 

    Nothing to disclose

    Stuart P. Feldman, MD

    Nothing to disclose

    Asutosh “Bobby” Gor, MD           

    Nothing to disclose

    Marilyn Haas, PhD, RN, CNS, ANP-BC

    Nothing to disclose

    Ali McBride, PharmD, MS, BCOP

    Advisor: Bristol Myers Squibb

    Chuck Miller, MD              

    Nothing to disclose

    Robert Mocharnuk, MD     

    Common stock: Merck

    Dee Morgillo, MEd.,CHCP

    Nothing to disclose

    Gene Saylors, MD

    Nothing to disclose

    Mary Stanley

    Nothing to disclose

    Emily Touloukian, DO       

    Nothing to disclose

    Disclaimer  
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Method of Participation and Request for Credit     
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • ASCO Direct™ Highlights - Leukemias and Lymphomas

    Contains 5 Component(s), Includes Credits

    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Release Date:  August 30, 2019
    Expire Date:  August 30, 2020
    Estimated time to complete: 30 minutes

    This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

    This activity is supported in part by educational grants from Astellas and Seattle Genetics, Amgen, Celgene Corporation, Daiichi Sankyo, Inc., Lilly, Merck & Co. Inc., and TESARO, Inc.

    Target Audience
    The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.

    Overview
    ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.

    Objectives
    At the end of this educational activity, participants should be able to:

    • Review highlights of the advances in clinical and translational research in leukemia and lymphoma presented at the 2019 ASCO® Annual Meeting
    • Identify emerging trends and strategies designed to improve the quality of care in leukemia and lymphoma
    • Evaluate tools and resources for the management of leukemia and lymphoma that can be used to achieve effective cancer care delivery and improve the patient experience

    Your Faculty
    Ryan Lynch, MD
    Assistant Professor, University of Washington
    Assistant Member, Fred Hutchinson Cancer Research Center
    Attending Physician, Seattle Cancer Care Alliance

    CONTINUING EDUCATION
    Accreditation Statement

    image

    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    image

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.



    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education credit. JA4008106-9999-19-043-H01-P

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information
    For information about the accreditation of this program please contact AXIS at info@axismeded.org.

    Disclosure of Conflicts of Interest
    AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    The faculty, Ryan Lynch, MD reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: Research grant: Takeda Oncology; Juno Therapeutics; Rhizen Pharmaceuticals SA; Incyte Corporation; TG Therapeutics, Inc. 

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Name of Planner/Manager/Reviewer

    Reported Financial Relationship

    John Allan, MD

    Advisor/Consultant: Abbvie, Genentech, Pharmacyclics, Sunesis, Verastem, Bayer, Janssen, AstraZeneca

    Keola Beale, MD

    Nothing to disclose

    Leigh Boehmer, PharmD, BCOP

    Nothing to disclose

    Jennie Crews, MD, MMM, FACP 

    Nothing to disclose

    Stuart P. Feldman, MD

    Nothing to disclose

    Asutosh “Bobby” Gor, MD           

    Nothing to disclose

    Marilyn Haas, PhD, RN, CNS, ANP-BC

    Nothing to disclose

    Ali McBride, PharmD, MS, BCOP

    Advisor: Bristol Myers Squibb

    Chuck Miller, MD              

    Nothing to disclose

    Robert Mocharnuk, MD     

    Common Stock: Merck

    Dee Morgillo, MEd.,CHCP

    Nothing to disclose

    Gene Saylors, MD

    Nothing to disclose

    Mary Stanley

    Nothing to disclose

    Emily Touloukian, DO       

    Nothing to disclose

    Disclaimer  
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Method of Participation and Request for Credit     
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.